Oral solid dosage forms offer a variety of release profiles for specific therapies. Yet, fine-tuning the exact delivery method can be an obstacle for manufacturers, notes Jim Baxter, North America Technical Business Development Manager at Lubrizol.
Extended-release (ER) oral solid dose tablets provide an effective solution when drug release is required for a longer time or as a preferred option to increase patient compliance — a growing challenge when creating therapies that meet patient needs.
The National Institutes of Health (NIH) found that 75% of patients failed to take their medication as directed, potentially leading to suboptimal treatment outcomes.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.